IN PURSUIT OF INCREASING CURE RATE OF LUNG CANCER
MISSION
At Onconox, we are persistently committed to significantly improving the lives of lung cancer patients by boosting the cure rate. We endeavour this by boosting patient adherence and reducing the deleterious consequences associated with standard medical care.
LUNG CANCER
Lung cancer is the world’s second most frequent disease, with 2.1 million new cases and 1.8 million deaths in 2018.
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are both included in most lung cancer statistics. SCLC accounts for 10 to 15% of all lung malignancies whereas NSCLC accounts for 80 to 85%.
News & Events
Onconox Welcomes Geoff Muckle as Interim CEO
Onconox is thrilled to announce the appointment of Geoff Muckle as Interim CEO. With over 20 years of experience in oncology innovation and pharmaceutical leadership, Geoff will drive the company’s growth and development.
Dr. Justin Stebbing Joins The Team
Onconox recruited high profile and internationally reputed Oncologist Dr. Justin Stebbing to the board.
Onconox Achieves Milestone In Funding Round
Onconox successfully closed seed round that will bring the lead program to the clinic.
